Article | October 10, 2018

How Biopharma Is Capitalizing On The Antibody Boom

Source: Cytiva

By G√ľnter Jagschies

Money profit

This article originally appeared in: the Medicine Maker.

Since the 1990s, antibodies have been the leading category of biotherapeutics (see Figure 1) – both in terms of the development pipeline and the approved range of biotherapeutics. Because of their unique ability to target almost any disease mechanism we can think of, they have a very wide range of medical indications. Using an antibody-based therapeutic also tends to reduce the risk of side effects, improving patient tolerance.

The wide applicability of antibodies has made them a key driver of revenue growth in the biopharma industry (see Figure 2) – today, they still represent over 50 percent of its overall revenue. The majority of antibody treatments currently focus on cancer and autoimmune disease, plus a few rare diseases, such as hemophilia A, as well as a handful of infectious diseases. Growth in the cancer and autoimmune categories is likely to continue – there are a large number of patients in need of treatment and many disease mechanisms to which antibodies can be directed. And this is reflected by biopharma’s R&D portfolio.

VIEW THE ARTICLE!
Signing up provides unlimited access to:
Signing up provides unlimited access to:
  • Trend and Leadership Articles
  • Case Studies
  • Extensive Product Database
  • Premium Content
HELLO. PLEASE LOG IN. X

Not yet a member of Biosimilar Development? Register today.

ACCOUNT SIGN UP X
Please fill in your account details
Login Information
I'm interested in newsletter subscriptions.
ACCOUNT SIGN UP

Subscriptions

Sign up for the newsletter that brings you the industry's latest news, technologies, trends and products.

You might also want to: